Camrelizumab and apatinib is named as a drug or biological intervention in 4 clinical trials in our China trial register, 4 of which are recruiting. Lead sponsors include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2), Linhui Peng (1) and Guangzhou Virotech Pharmaceutical Co., Ltd. (1). Registered phases: Phase 3, Phase 2 and Phase 2/3. Conditions studied include Chemotherapy Effect; BCLC Stage C Hepatocellular Carcinoma; Hepato Cellular Carcinoma (HCC).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (ClinicalTrials.gov ↗) BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect |
Phase 3 | Recruiting |
| NCT07267806 | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC (ClinicalTrials.gov ↗) Hepato Cellular Carcinoma (HCC), Chemotherapy Effect |
Phase 3 | Recruiting |
| NCT07589244 | A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC (ClinicalTrials.gov ↗) HCC |
Phase 2/3 | Recruiting |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria (ClinicalTrials.gov ↗) Hepatocellular Carcinoma Non-resectable |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Chemotherapy Effect | 2 |
| BCLC Stage C Hepatocellular Carcinoma | 1 |
| Hepato Cellular Carcinoma (HCC) | 1 |
| Hepatocellular Carcinoma Non-resectable | 1 |
| HCC | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Linhui Peng | 1 |
| Guangzhou Virotech Pharmaceutical Co., Ltd. | 1 |
| Register | Camrelizumab and apatinib trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Camrelizumab and apatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Camrelizumab and apatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.